Illumina wins chance to battle Complete Genomics over patents

Illumina ($ILMN), a gene sequencer and diagnostics company, will renew a push to continue its patent fight against Complete Genomics ($GNOM). The U.S. District Court for the Northern District of California granted the company's request to file a motion seeking reconsideration of its October ruling invalidating patent claims against Complete Genomics.  Previously, the court invalidated two of Illumina's claims. The continued court fight comes after Complete Genomics rebuffed a takeover bid from Illumina in favor of a Chinese suitor. Release

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.